Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
September 23, 2020
Publication date:
January 14, 2021
Applicant:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
September 24, 2020
Publication date:
January 14, 2021
Applicant:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: In one aspect, the present invention provides heterodimeric antibodies comprising a first monomer comprising a first heavy chain constant domain comprising a first variant Fc domain and a first antigen binding domain and a second monomer comprising a second heavy chain constant domain comprising a second variant Fc domain and a second antigen binding domain. In an additional aspect the heterodimeric antibody comprises a first monomer comprising a heavy chain comprising a first Fc domain and a single chain Fv region (scFv) that binds a first antigen, wherein the scFv comprises a charged scFv linker. The heterodimeric antibody further comprises a second monomer comprising a first heavy chain comprising a second Fc domain and a first variable heavy chain and a first light chain.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
December 8, 2020
Assignee:
Xencor, Inc.
Inventors:
Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
Abstract: The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.
Type:
Grant
Filed:
October 10, 2012
Date of Patent:
December 1, 2020
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, Gregory L. Moore, John Desjarlais, Rumana Rashid
Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
Type:
Application
Filed:
April 1, 2020
Publication date:
October 8, 2020
Applicant:
XENCOR, INC.
Inventors:
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Abstract: The present invention is directed to compositions that include programmed cell death 1 (PD-1) binding domains and antibodies that include such PD-1 binding domains. Also provided are nucleic acid compositions that encode the binding domains and antibodies, expression vector compositions that include the nucleic acids, and host cells that include the expression vector compositions.
Type:
Grant
Filed:
June 14, 2017
Date of Patent:
September 29, 2020
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, Gregory Moore, John Desjarlais, Michael Hedvat, Christine Bonzon, Alex Nisthal
Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.
Type:
Grant
Filed:
April 2, 2018
Date of Patent:
August 25, 2020
Assignees:
ALLERGAN, INC., XENCOR, INC.
Inventors:
Peter C. Baciu, Yanbin Liang, Jason Guu, Matthew Bernett, Umesh Muchhal, John Desjarlais
Abstract: The present disclosure is directed to a method of treating neurological disorder comprising measuring c-reactive protein in a patient and peripherally administering to the patient a DN-TNF polypeptide that inhibits the activity of soluble TNF-but not transmembrane TNF-?.
Type:
Application
Filed:
April 1, 2019
Publication date:
June 4, 2020
Applicant:
XENCOR, INC.
Inventors:
David Szymkowski, Malu Tansey, Lesley Probert
Abstract: The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc?R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.
Type:
Grant
Filed:
September 22, 2017
Date of Patent:
April 21, 2020
Assignee:
Xencor, Inc.
Inventors:
Matthew J. Bernett, Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Erik Weiking Pong, John O. Richards, Eugene Alexander Zhukovsky
Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Grant
Filed:
September 21, 2018
Date of Patent:
March 10, 2020
Assignee:
Xencor, Inc.
Inventors:
Gregory Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
Type:
Application
Filed:
November 14, 2019
Publication date:
March 5, 2020
Applicant:
XENCOR, INC.
Inventors:
Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
Abstract: The present disclosure relates generally to anti-CD39 antibodies, including antibody-drug conjugates comprising the antibodies, and methods of their use.
Type:
Grant
Filed:
November 6, 2015
Date of Patent:
February 11, 2020
Assignee:
Xencor, Inc.
Inventors:
Guoqing Chen, Gregory M. Hayes, Jan-Willem Theunissen, Edward Thein H. Van Der Horst, Leonard G. Presta
Abstract: The present invention is directed to novel bispecific heterodimeric Fc fusion proteins comprising an IL-15/IL-15R? Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein.
Type:
Grant
Filed:
October 16, 2017
Date of Patent:
February 4, 2020
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, Rumana Rashid, John Desjarlais, Rajat Varma, Christine Bonzon
Abstract: The present invention relates to methods and compositions for modulating T cells. The modulation includes suppressing or inducing regulatory T cells or cytotoxic T cells.
Type:
Grant
Filed:
March 17, 2014
Date of Patent:
January 28, 2020
Assignee:
Xencor, inc.
Inventors:
Seung Chu, Matthew Bernett, Dilki Wickramarachchi, John Desjarlais